Lars Wagner

Overview:

I am a pediatric oncologist with a clinical and research focus on the care of adolescents and young adults with sarcoma. I have led multiple institutional and national clinical trials exploring new therapies for patients with recurrent sarcoma, and am interested in new drug development and identification of predictive biomarkers.

Positions:

Professor of Pediatrics

Pediatrics, Hematology-Oncology
School of Medicine

Chief, Division of Hematology/Oncology

Pediatrics, Hematology-Oncology
School of Medicine

Member of the Duke Cancer Institute of the

Duke Cancer Institute
School of Medicine

Education:

M.D. 1991

University of Kentucky, College of Medicine

Residency, Pediatrics

University of Tennessee Health Science Center

Hematology/Oncology Fellowship, St Jude Children's Hospital

University of Tennessee Health Science Center

Grants:

Per Case Reimbursement : NIH National Clinical Trials Network (NCTN)

Administered By
Pediatrics, Hematology-Oncology
Awarded By
Children's Hospital of Philadelphia
Role
Principal Investigator
Start Date
End Date

A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in combination with Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma (CL-PTL-130)

Administered By
Pediatrics, Hematology-Oncology
Awarded By
Gradalis, Inc.
Role
Principal Investigator
Start Date
End Date

Workload Intensity NIH National Clinical Trials Network (NCTN)

Administered By
Pediatrics, Hematology-Oncology
Awarded By
Children's Hospital of Philadelphia
Role
Principal Investigator
Start Date
End Date

NCI Community Oncology Research Program (NCORP) Research Base Grant

Administered By
Pediatrics, Hematology-Oncology
Awarded By
Children's Hospital of Philadelphia
Role
Principal Investigator
Start Date
End Date

Project: One Time EOY, Integrated BIQSFP AAML1031- Echocardiogram Reports and Images

Administered By
Pediatrics, Hematology-Oncology
Awarded By
Children's Hospital of Philadelphia
Role
Principal Investigator
Start Date
End Date

Publications:

A PHASE I TRIAL OF MK-0752 IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY CNS MALIGNANCIES: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY

Authors
Fouladi, M; Olson, J; Stewart, C; Kocak, M; Onar-Thomas, A; Wagner, L; Packer, R; Goldman, S; Gururangan, S; Blaney, S; Pollack, I; Smith, C; Demuth, T; Kun, L; Boyett, J; Gilbertson, R
MLA Citation
Fouladi, Maryam, et al. “A PHASE I TRIAL OF MK-0752 IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY CNS MALIGNANCIES: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY.” Neuro Oncology, vol. 14, OXFORD UNIV PRESS INC, 2012, pp. 115–115.
URI
https://scholars.duke.edu/individual/pub929221
Source
wos
Published In
Neuro Oncology
Volume
14
Published Date
Start Page
115
End Page
115

Management of recurrent Ewing sarcoma: challenges and approaches.

Although many patients with newly diagnosed Ewing sarcoma can become long-term survivors, relapse remains an important clinical problem for which there is no standard approach. Several prognostic factors have been identified, and these may help guide patient counseling and therapy decisions. A variety of chemotherapy regimens have produced responses in patients with recurrent Ewing sarcoma, but no comparative studies have been completed to show superiority of any one particular approach. In addition, the optimum length of therapy for salvage regimens and use of local control measures remains unknown. The likelihood of cure remains low and the gaps in our knowledge are great, and so enrollment on clinical trials should be strongly encouraged for these patients when feasible. Because Ewing sarcoma is relatively rare, some pediatric and adult oncologists may be less familiar with the management of relapsed patients. In this review, we address common questions facing the clinician and patient, and provide an update on new strategies for therapy.
MLA Citation
Van Mater, David, and Lars Wagner. “Management of recurrent Ewing sarcoma: challenges and approaches.Onco Targets Ther, vol. 12, 2019, pp. 2279–88. Pubmed, doi:10.2147/OTT.S170585.
URI
https://scholars.duke.edu/individual/pub1381184
PMID
30988632
Source
pubmed
Published In
Oncotargets and Therapy
Volume
12
Published Date
Start Page
2279
End Page
2288
DOI
10.2147/OTT.S170585